Pfizer Inc. (NYSE: PFE – Get Rating) – Research analysts at SVB Leerink boosted their Q2 2022 earnings per share (EPS) estimates for shares of Pfizer in a report released on Wednesday, June 22nd. SVB Leerink analyst D. Risinger now forecasts that the biopharmaceutical company will earn $ 1.74 per share for the quarter, up from their previous estimate of $ 1.32. SVB Leerink currently has a “Market Perform” rating and a $ 55.00 target price on the stock. The consensus estimate for Pfizer’s current full-year earnings is $ 6.61 per share. SVB Leerink also issued estimates for Pfizer’s Q4 2022 earnings at $ 1.48 EPS and FY2026 earnings at $ 4.47 EPS.
Pfizer (NYSE: PFE – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 EPS for the quarter, missing the consensus estimate of $ 1.66 by ($ 0.04). The firm had revenue of $ 25.66 billion for the quarter, compared to the estimate consensus of $ 24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. Pfizer’s revenue for the quarter was up 76.8% compared to the same quarter last year. During the same quarter last year, the company posted $ 0.93 earnings per share.
PFE has been the topic of several other reports. Wells Fargo & Company reduced their price target on Pfizer from $ 60.00 to $ 55.00 in a research report on Wednesday, May 4th. Berenberg Bank set a $ 50.00 price target on Pfizer in a research report on Friday, May 27th. Morgan Stanley initiated coverage on Pfizer in a research report on Wednesday, April 6th. They set an “equal weight” rating and a $ 55.00 price target on the stock. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. Finally, The Goldman Sachs Group set a $ 51.00 price target on Pfizer in a research report on Wednesday, May 25th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $ 57.26.
Shares of Pfizer stock opened at $ 51.59 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $ 289.47 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 0.61 and a beta of 0.76. The business’s 50-day moving average price is $ 50.48 and its 200-day moving average price is $ 52.21. Pfizer has a 12 month low of $ 38.82 and a 12 month high of $ 61.71.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be given a dividend of $ 0.40 per share. This represents a $ 1.60 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.
In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $ 53.96, for a total value of $ 227,603.28. Following the completion of the sale, the senior vice president now owns 10,846 shares of the company stock, valued at approximately $ 585,250.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction on Monday, May 16th. The stock was sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the completion of the sale, the senior vice president now directly owns 15,064 shares of the company stock, valued at approximately $ 760,732. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,126 shares of company stock valued at $ 2,075,003. 0.05% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of PFE. Bank OZK increased its holdings in Pfizer by 0.3% during the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company stock worth $ 4,067,000 after purchasing an additional 195 shares during the period. TimeScale Financial Inc. increased its holdings in Pfizer by 2.9% during the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company stock worth $ 412,000 after purchasing an additional 196 shares during the period. Fruth Investment Management increased its holdings in Pfizer by 0.7% during the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company stock worth $ 1,730,000 after purchasing an additional 200 shares during the period. Winfield Associates Inc. increased its holdings in Pfizer by 0.9% during the 4th quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company stock worth $ 1,273,000 after purchasing an additional 200 shares during the period. Finally, Birinyi Associates Inc. increased its holdings in Pfizer by 3.4% during the 1st quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company stock worth $ 311,000 after purchasing an additional 200 shares during the period. 66.50% of the stock is owned by institutional investors and hedge funds.
About Pfizer: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.